Sweden Hereditary Angioedema Therapeutic Market (2025-2031) | Share, Segmentation, Industry, Forecast, Growth, Size & Revenue, Analysis, Value, Outlook, Trends, Companies, Competitive Landscape

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 Sweden Country Macro Economic Indicators

3.2 Sweden Hereditary Angioedema Therapeutic Market Revenues & Volume, 2021 & 2031F

3.3 Sweden Hereditary Angioedema Therapeutic Market - Industry Life Cycle

3.4 Sweden Hereditary Angioedema Therapeutic Market - Porter's Five Forces

3.5 Sweden Hereditary Angioedema Therapeutic Market Revenues & Volume Share, By Type, 2021 & 2031F

3.6 Sweden Hereditary Angioedema Therapeutic Market Revenues & Volume Share, By Drug Class, 2021 & 2031F

3.7 Sweden Hereditary Angioedema Therapeutic Market Revenues & Volume Share, By Application, 2021 & 2031F

3.8 Sweden Hereditary Angioedema Therapeutic Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing awareness about hereditary angioedema (HAE) among healthcare professionals and patients.

4.2.2 Advances in research and development leading to the introduction of novel therapies for HAE.

4.2.3 Growing prevalence of HAE in Sweden, leading to a larger target patient population.

4.2.4 Supportive government initiatives and policies for rare disease management.

4.2.5 Rising healthcare expenditure and improved access to healthcare services.

4.3 Market Restraints

4.3.1 High cost associated with HAE therapies may limit accessibility for some patients.

4.3.2 Limited availability of specialized healthcare facilities for HAE diagnosis and treatment.

4.3.3 Challenges in early diagnosis and effective management of HAE cases.

4.3.4 Potential side effects and safety concerns associated with HAE treatments.

4.3.5 Competition from alternative treatment options and therapies for HAE.

6.1 Sweden Hereditary Angioedema Therapeutic Market, By Type

6.1.1 Overview and Analysis

6.1.2 Sweden Hereditary Angioedema Therapeutic Market Revenues & Volume, By Type, 2021- 2031F

6.1.3 Sweden Hereditary Angioedema Therapeutic Market Revenues & Volume, By Type I Hereditary Angioedema (HAE), 2021- 2031F

6.1.4 Sweden Hereditary Angioedema Therapeutic Market Revenues & Volume, By Type II Hereditary Angioedema (HAE), 2021- 2031F

6.1.5 Sweden Hereditary Angioedema Therapeutic Market Revenues & Volume, By Type III Hereditary Angioedema (HAE), 2021- 2031F

6.2 Sweden Hereditary Angioedema Therapeutic Market, By Drug Class

6.2.1 Overview and Analysis

6.2.2 Sweden Hereditary Angioedema Therapeutic Market Revenues & Volume, By C-1 Esterase Inhibitors, 2021- 2031F

6.2.3 Sweden Hereditary Angioedema Therapeutic Market Revenues & Volume, By Bradykynin B2 Receptor Antagonist, 2021- 2031F

6.2.4 Sweden Hereditary Angioedema Therapeutic Market Revenues & Volume, By Kallikrein Inhibitors, 2021- 2031F

6.2.5 Sweden Hereditary Angioedema Therapeutic Market Revenues & Volume, By Others, 2021- 2031F

6.3 Sweden Hereditary Angioedema Therapeutic Market, By Application

6.3.1 Overview and Analysis

6.3.2 Sweden Hereditary Angioedema Therapeutic Market Revenues & Volume, By Prophylaxis, 2021- 2031F

6.3.3 Sweden Hereditary Angioedema Therapeutic Market Revenues & Volume, By Treatment, 2021- 2031F

6.4 Sweden Hereditary Angioedema Therapeutic Market, By Route of Administration

6.4.1 Overview and Analysis

6.4.2 Sweden Hereditary Angioedema Therapeutic Market Revenues & Volume, By Oral, 2021- 2031F

6.4.3 Sweden Hereditary Angioedema Therapeutic Market Revenues & Volume, By Injectable, 2021- 2031F

7.1 Sweden Hereditary Angioedema Therapeutic Market Export to Major Countries

7.2 Sweden Hereditary Angioedema Therapeutic Market Imports from Major Countries

8.1 Number of patients diagnosed with HAE annually in Sweden.

8.2 Adoption rate of novel HAE therapies in the market.

8.3 Average time taken for HAE diagnosis and initiation of treatment.

8.4 Patient satisfaction levels with HAE treatment outcomes.

8.5 Rate of hospitalization and emergency room visits for HAE-related complications.

9.1 Sweden Hereditary Angioedema Therapeutic Market Opportunity Assessment, By Type, 2021 & 2031F

9.2 Sweden Hereditary Angioedema Therapeutic Market Opportunity Assessment, By Drug Class, 2021 & 2031F

9.3 Sweden Hereditary Angioedema Therapeutic Market Opportunity Assessment, By Application, 2021 & 2031F

9.4 Sweden Hereditary Angioedema Therapeutic Market Opportunity Assessment, By Route of Administration, 2021 & 2031F

10.1 Sweden Hereditary Angioedema Therapeutic Market Revenue Share, By Companies, 2024

10.2 Sweden Hereditary Angioedema Therapeutic Market Competitive Benchmarking, By Operating and Technical Parameters